Filgotinib | search
Click here to view Filgotinib news from 60+ newspapers.
Bookmark or Share- Filgotinib - WikipediaFilgotinib is a Janus kinase inhibitor with selectivity for subtype JAK1 of this enzyme. It is considered a promising agent as it inhibits JAK1 selectively, similar to already marketed upadacitinib .
- Filgotinib: What is it and is it FDA approved? - Drugs.comFilgotinib is an oral, selective JAK1 inhibitor in development for the treatment of adults with moderate-to-severe rheumatoid arthritis (RA). Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
- Filgotinib | Side-effects, uses, time to work - Versus ArthritisFilgotinib, also known by the trade name Jyseleca, is a type of drug known as a JAK inhibitor. These drugs work by limiting the action of Janus kinase enzymes, which are involved in the inflammation that causes the symptoms of rheumatoid arthritis and some other conditions.
- Jyseleca (filgotinib - European Medicines AgencyFilgotinib, the active substance in Jyseleca, reduces the activity of the immune system. It does this by blocking the action of enzymes known as Janus kinases (JAKs). These enzymes play an important role in the inflammatory processes that occur in rheumatoid arthritis and ulcerative colitis.
- Filgotinib | Drugs | BNF | NICEFilgotinib is a selective inhibitor of the Janus-associated tyrosine kinase JAK1. 200 mg once daily, a reduced dose of 100 mg once daily is recommended for patients with certain risk factors—consult product literature, for treatment interruption due to side-effects—consult product literature.
More
